SAB Biotherapeutics (SABS) Fundamentals 2026 — P/E 8.3x, Revenue Analysis | SniperIQ
SAB Biotherapeutics (SABS) is a US-listed Healthcare company in Biotechnology with a market capitalization of
SAB Biotherapeutics (SABS) has a market capitalization of approximately
SAB Biotherapeutics's trailing twelve-month P/E ratio is 8.3x, with a price-to-book (P/B) of 0.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
SAB Biotherapeutics runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
SAB Biotherapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
SAB Biotherapeutics carries a debt-to-equity ratio of 0.03x and a current ratio of 11.45x, with a market beta of 0.53. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For SAB Biotherapeutics (SABS) the key facts are: market cap
Get SAB Biotherapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.